Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Children's Oncology Group
MediLink Therapeutics (Suzhou) Co., Ltd.
Alliance for Clinical Trials in Oncology
Seagen Inc.
CSPC Megalith Biopharmaceutical Co.,Ltd.
Gilead Sciences
AstraZeneca
AstraZeneca
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Maia Biotechnology
Bristol-Myers Squibb
Intergroupe Francophone de Cancerologie Thoracique
Sun Yat-sen University
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Japan Breast Cancer Research Group
Spanish Breast Cancer Research Group
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sichuan Baili Pharmaceutical Co., Ltd.
National Cancer Institute (NCI)
Shanghai Yizhong Pharmaceutical Co., Ltd.
Hoffmann-La Roche
Gilead Sciences
Qilu Pharmaceutical Co., Ltd.
AstraZeneca
Shanghai Chest Hospital
University of Ulm
Sun Yat-sen University
RemeGen Co., Ltd.
Sun Yat-sen University
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Spanish Breast Cancer Research Group
Nektar Therapeutics
Agenus Inc.
Gilead Sciences
Children's Oncology Group
Merck Sharp & Dohme LLC
Betta Pharmaceuticals Co., Ltd.
Vejle Hospital
Children's Oncology Group
Centre Hospitalier Universitaire de Besancon
Zhejiang Cancer Hospital
CTI BioPharma
Sun Yat-sen University
Canadian Cancer Trials Group
Fudan University